Search
Close this search box.

Webinar – A Biomarker Journey In Immuno-Oncology Utilizing Immunohistochemistry – Cerba Research

In immuno-oncology (IO) research, biomarkers present the opportunity to identify and target the patient response to a potential new therapeutic, but how can it be integrated into a clinical development plan to increase the effectiveness of clinical trials?

With immunohistochemistry (IHC) technology, biomarkers can be identified in tumor biopsies. IHC provides the possibility to better understand biomarker mechanisms in the tumor’s environment. By implementing a robust biomarker validation process, sponsors will increase the success of biomarker integration in their clinical trials. 

Cerba Research – Webinar – A Biomarker Journey in Immuno-Oncology Utilizing Immunohistochemistry

Cerba Research - Webinar - A Biomarker Journey in Immuno-Oncology Utilizing Immunohistochemistry -Thumbnail and Playbutton

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to  our experts to see how we can help advance your clinical trial

Contact Us